Cholinergic stimulation with pyridostigmine reduces the QTc interval in coronary artery disease
Braz. j. med. biol. res
; 35(6): 685-689, June 2002. ilus, tab
Article
em En
| LILACS
| ID: lil-309517
Biblioteca responsável:
BR1.1
ABSTRACT
Parasympathetic dysfunction is an independent risk factor in patients with coronary artery disease; thus, cholinergic stimulation is a potential therapeutic measure that may be protective by acting on ventricular repolarization. The purpose of the present study was to determine the effects of pyridostigmine bromide (PYR), a reversible anticholinesterase agent, on the electrocardiographic variables, particularly QTc interval, in patients with stable coronary artery disease. In a randomized double-blind crossover placebo-controlled study, simultaneous 12-lead electrocardiographic tracings were obtained at rest from 10 patients with exercise-induced myocardial ischemia before and 2 h after the oral administration of 45 mg PYR or placebo. PYR increased the RR intervals (pre 921 ± 27 ms vs post 1127 ± 37 ms; P<0.01) and, in contrast with placebo, decreased the QTc interval (pre 401 ± 3 ms vs post 382 ± 3 ms; P<0.01). No other electrocardiographic variables were modified (PR segment, QT interval, QT and QTc dispersions). Cholinergic stimulation with PYR caused bradycardia and reduced the QTc interval without important side effects in patients with coronary disease. These effects, if confirmed in studies over longer periods of administration, may suggest a cardioprotection by cholinergic stimulation with PYR
Texto completo:
1
Índice:
LILACS
Assunto principal:
Brometo de Piridostigmina
/
Inibidores da Colinesterase
/
Doença das Coronárias
Tipo de estudo:
Clinical_trials
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Revista:
Braz. j. med. biol. res
Assunto da revista:
BIOLOGIA
/
MEDICINA
Ano de publicação:
2002
Tipo de documento:
Article
/
Project document